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acid-fast bacilli (AFB)— mycobacteria that when stained, retain color even after they 
have been washed in an acid solution; may be detected under a microscope in a 
stained smear
adherence to treatment— following the recommended course of treatment by 
taking all the prescribed medications for the entire recommended time
administrative controls— the first level in the hierarchy of TB infection-control 
measures; managerial measures that reduce the risk for exposure to persons who 
have or are suspected to have TB disease
adverse reaction— negative side effect resulting from the use of a drug (for 
example, hepatitis, nausea, headache)
AIDS— acquired immunodeficiency syndrome, a condition in which the immune 
system is weakened and therefore less able to fight certain infections and diseases; 
AIDS is caused by infection with the human immunodeficiency virus (HIV)
airborne infection isolation (AII) room— formerly called “negative pressure 
isolation room.” A room with special characteristics to prevent the spread of droplet 
nuclei expelled by a TB patient, including negative-pressure ventilation. 
alveoli— the small air sacs of the lung that are at the end of the airway; when 
droplet nuclei reach these air sacs, TB infection begins
anergy— the inability to react to a skin test because of a weakened immune system, 
often caused by HIV infection or severe illness 
antigen— protein substances that can produce an immune response (such as  
CFP-10, ESAT-6, or those in PPD)
antiretroviral therapy (ART)— a lifelong combination drug treatment to suppress 
HIV and improve the quality and length of life for a person living with HIV/AIDS
bacteriologic examination— tests done in a mycobacteriology laboratory to 
aid diagnosis of TB disease; includes examining a specimen under a microscope, 
culturing the specimen, and testing for drug susceptibility
baseline skin test— a tuberculin skin test (TST) given to employees or residents 
in certain facilities when they start their job or enter the facility (see TB testing 
program and two-step testing)
BCG— bacille Calmette-Guérin (BCG), a vaccine for TB disease that is used in many 
countries but rarely used in the United States; may cause a false-positive reaction to 
the TST but does not affect interferon-gamma release assay (IGRA) results
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boosted reaction— a positive reaction to a TST, due to a boosted immune 
response from a skin test given up to a year earlier; occurs in people who were 
infected a long time ago and whose ability to react to tuberculin has lessened. Two-
step testing is used in TB testing programs to tell the difference between boosted 
reactions and reactions caused by recent infection (see booster phenomenon and 
two-step testing).
booster phenomenon— a phenomenon in which people (especially older adults) 
who are skin tested many years after becoming infected with M. tuberculosis may 
have a negative reaction to an initial TST, followed by a positive reaction to a TST 
given up to a year later; this happens because the first TST boosts the immune 
response. Two-step testing is used in TB testing programs to tell the difference 
between boosted reactions and reactions caused by recent infection (see two-step 
testing).
bronchoscopy— a procedure used to obtain pulmonary secretions or lung tissue 
with an instrument called a bronchoscope; used only when patients cannot cough 
up sputum on their own and an induced specimen cannot be obtained
case management— a strategy health departments can use to manage patient care 
and help ensure patients successfully complete treatment 
case rate— the number of cases that occur during a certain time period, divided by 
the size of the population during that time period; the case rate is often expressed 
in terms of a population size of 100,000 persons
cavity— a hollow space within the lung, visible on a chest x-ray, that may contain 
many tubercle bacilli; often occurs in people with severe pulmonary TB disease
CFP-10— one of the antigens used in IGRAs that is found in M. tuberculosis strains 
but not in BCG vaccine strains
civil surgeons— domestic health care providers who screen immigrants living in the 
United States and applying for a permanent residence visa or citizenship 
clinical evaluation— an evaluation done to find out whether a patient has 
symptoms or signs of TB disease or is responding to treatment; also done to check 
for adverse reactions to TB medications
clinician— a physician, physician’s assistant, or nurse
colonies— groups of mycobacteria that have grown on solid media
congregate setting— a setting in which a group of persons reside, meet, or gather 
either for a limited or extended period of time in close physical proximity. Examples 
include prisons, nursing homes, schools, and homeless shelters.
contacts— persons exposed to someone with infectious TB disease; can include 
family members, roommates or housemates, close friends, coworkers, classmates, 
and others
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continuation phase— the period after the first 8 weeks of TB disease treatment, 
during which tubercle bacilli that remain after the initial phase are treated with at 
least two drugs
control— a standard of comparison for checking or verifying the results of an 
experiment 
corticosteroid— a type of steroid, either natural or man-made, often used to treat 
arthritis, certain allergies, or other immune disorders
cough-inducing procedures— procedures that make a patient cough, such as 
sputum induction and bronchoscopy
culture— to grow organisms in media (substances containing nutrients) so that they 
or the product of this process can be identified; a positive culture for  
M. tuberculosis contains tubercle bacilli, whereas a negative culture contains no 
detectable tubercle bacilli
daily regimen— a treatment schedule in which the patient takes a dose of each 
prescribed medication every day
diabetes mellitus— a disease in which blood glucose levels are above normal; 
diabetes can increase susceptibility to some infectious diseases, including TB
diagnostic evaluation— an evaluation used to diagnose TB disease; includes 
a medical history, a chest x-ray, the collection of specimens for bacteriologic 
examination, and possibly a tuberculin skin test or an interferon-gamma release 
assay (blood test)
directly observed therapy (DOT)— a strategy devised to help patients adhere to 
treatment; a designated person watches the TB patient swallow each dose of the 
prescribed drugs to ensure adherence and tolerability of the regimen
disseminated TB— TB disease that occurs when tubercle bacilli enter the 
bloodstream or lymph system and are carried to all parts of the body where they 
grow and cause disease in multiple sites, e.g., miliary TB
droplet nuclei— very small droplets (1 to 5 microns in diameter) containing  
M. tuberculosis that may be expelled when a person who has infectious TB coughs, 
sneezes, speaks, or sings; the droplets can remain suspended in the air for several 
hours, depending on the environment 
drug-resistant TB— TB caused by M. tuberculosis organisms that are able to grow 
in the presence of a particular drug; TB that is resistant to at least one anti-TB drug
drug susceptibility pattern— the list of antituberculosis drugs to which a strain of 
tubercle bacilli is susceptible and to which it is resistant
environmental controls— the second level in the hierarchy of TB infection-control 
measures; engineering systems used to prevent the transmission of TB in health care 
settings, including ventilation, high-efficiency particulate air (HEPA) filtration, and 
ultraviolet germicidal irradiation
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epidemiology— the study of the distribution and causes of disease and other 
health problems in different groups of people
erythema— redness around the site of the injection when a TST is done; erythema 
is not measured as part of the reaction size because redness does not indicate that 
a person has TB infection
ESAT-6— one of the antigens used in IGRAs that is found in M. tuberculosis strains 
but not in BCG vaccine strains
ethambutol (EMB)— a drug used to treat TB disease; may cause vision problems. 
Ethambutol should be used cautiously in children who are too young to be 
monitored for changes in their vision.
exposure to TB— time spent with or near someone who has infectious TB disease
extensively drug-resistant TB (XDR TB)— a type of MDR TB that is resistant to 
isoniazid and rifampin, plus resistant to any fluoroquinolone and at least one of 
three injectable anti-TB drugs (such as amikacin, kanamycin, or capreomycin)
extrapulmonary TB— TB disease that occurs in places other than the lungs, such 
as the lymph nodes, the pleura, the brain, the kidneys, or the bones; most types of 
extrapulmonary TB are not infectious
false-negative reaction— a negative reaction to the TST or IGRA in a person who 
has TB infection 
false-positive reaction— a positive reaction to the TST or IGRA in a person who 
does not have TB infection
first-line TB treatment drugs— of the approved drugs to treat TB, isoniazid, 
rifampin, ethambutol, and pyrazinamide are considered the first-line anti-TB drugs; 
they form the core of a standard treatment regimen. They are considered “first-
line” because together they constitute the most powerful, least expensive, and most 
tolerable treatment regimen.
fit check— see user seal check
fit test— a method to evaluate the fit of a respirator on a person
foreign-born persons— people born outside of the United States; foreign-born 
persons from areas of the world where TB is common (for example, Asia, Africa, 
Latin America, Eastern Europe, Russia, and the Caribbean) are more likely to be 
infected with M. tuberculosis
gastrectomy— a partial or full surgical removal of the stomach 
gastric washing— a procedure done by inserting a tube through the patient’s  
nose and passing it into the stomach; may be useful for obtaining a specimen for 
culture from children, who produce little or no sputum when they cough
GeneXpert— a semi-automated molecular diagnostic system. See Xpert  
MTB/RIF assay.
genotype— distinct genetic pattern of an organism 
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genotyping— a laboratory-based method that can determine the genetic pattern of 
the strain of M. tuberculosis that caused TB disease in a person
health care facilities— places where people receive health care, such as hospitals or 
clinics
health care setting— a place where health care is delivered; includes inpatient, 
outpatient settings, TB clinics, settings in which home-based health-care and 
emergency medical services are provided, and laboratories handling TB clinical 
samples
hepatitis— inflammation of the liver, causing symptoms such as nausea, vomiting, 
abdominal pain, fatigue, and brown urine; hepatitis can be caused by several drugs 
used to treat LTBI or TB disease
high efficiency particulate air (HEPA) filters— special filters that can be used in 
ventilation systems to help remove droplet nuclei from the air
HIV— human immunodeficiency virus, the virus that causes AIDS
immune system— cells and tissues in the body that protect the body from foreign 
substances
immunosuppressive therapy— therapy that suppresses, or weakens, the immune 
system
induced sputum— sputum that is obtained by having the patient inhale a saline 
(salt water) mist, causing the patient to cough deeply; this procedure is used to help 
patients cough up sputum if they cannot do so on their own
induration— swelling that can be felt around the site of injection after a TST is done; 
the reaction size is the diameter of the swollen area, measured across the forearm
infection control procedures— measures to prevent the spread of TB 
infectious— capable of spreading infection; a person who has infectious TB disease 
expels droplets containing M. tuberculosis into the air when he or she coughs, 
sneezes, speaks, or sings
infiltrate— a collection of fluid and cells in the tissues of the lung; visible on a chest 
x-ray in people with pulmonary TB disease
initial phase— the first 8 weeks of TB disease treatment, during which most of the 
tubercle bacilli are killed
interferon-gamma (IFN-γ)— protein that is normally produced by the body in 
response to infection. IGRA interpretations are based on the amount of IFN-γ that is 
released or on the number of cells that release IFN-γ.
interferon-gamma release assay (IGRA)— a type of blood test that measures 
a person’s immune reactivity to M. tuberculosis. In the United States, the 
QuantiFERON®-TB Gold In-Tube (QFT-GIT) and the T-SPOT®.TB test (T-Spot) are 
currently available IGRAs.
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intermittent therapy— a treatment schedule in which the patient takes each 
prescribed medication one, two, or three times weekly at the appropriate dosage
isolate— a group of organisms isolated or separated from a specimen; in an  
M. tuberculosis isolate, the organisms have been grown in culture and identified as 
M. tuberculosis
isoniazid (INH)— a drug that is used for treating LTBI and TB disease; although 
cheap and relatively safe, it may cause hepatitis and other adverse reactions in  
some patients
jejunoileal bypass— surgical operation performed to reduce absorption in the  
small intestine
latent TB infection (LTBI)— refers to the condition when a person is infected with  
M. tuberculosis but does not have TB disease. Persons with LTBI carry the organism 
that causes TB, but they do not have TB disease symptoms, and they cannot spread 
TB germs to others. Most persons with LTBI have a positive result to the tuberculin 
skin test or to an interferon-gamma release assay.
liver function tests— tests done to detect injury to the liver, such as hepatitis
LTBI treatment— medication that is given to people who have LTBI to prevent 
developing TB disease
malaise— a feeling of general discomfort or illness
Mantoux tuberculin skin test (TST)— a method of testing for TB infection; a needle 
and syringe are used to inject 0.1 ml (5 tuberculin units) of purified protein derivative 
(PPD) tuberculin solution between the layers of the skin (intradermally), usually on 
the forearm; the reaction to this test, usually a small swollen area (induration), is 
measured 48 to 72 hours after the injection and is interpreted as positive or negative 
depending on the size of the reaction and the patient’s risk factors for TB; the routine 
methodology for tuberculin skin testing worldwide; supersedes all older methods
media— substances containing special nutrients and used for growing cultures of 
bacteria found in specimens
medical history— the part of a patient’s life history that is important for diagnosing 
and treating TB infection or disease, including history of exposure, symptoms, 
previous diagnosis of TB infection or disease, and risk factors for TB disease
miliary TB— a type of disseminated TB disease that occurs when tubercle bacilli 
enter the bloodstream and are carried to all parts of the body, where they grow and 
cause disease in multiple sites; the chest x-ray of patients with miliary TB often looks 
like millet seeds scattered throughout the lung
mono-resistant TB— TB that is resistant to one TB treatment drug
multidrug-resistant TB (MDR TB)— TB that is resistant to at least the drugs isoniazid 
and rifampin; MDR TB is more difficult to treat than drug-susceptible TB
mycobacteria— a group of bacteria that can cause a variety of diseases
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mycobacteriology laboratory— a laboratory that deals specifically with  
M. tuberculosis and other mycobacteria
Mycobacterium avium-complex— a nontuberculous mycobacteria (NTM) that can 
cause opportunistic infections in immunocompromised persons; often disseminated 
infections
Mycobacterium bovis— a type of tuberculous mycobacteria that can cause a 
disease similar to TB; usually infects cows, but it can infect other mammals 
including humans. Before the pasteurization of milk became common practice, these 
mycobacteria were often spread to humans through contaminated milk; in the United 
States today, M. bovis rarely affects humans.
Mycobacterium tuberculosis complex— the M. tuberculosis complex includes seven 
other TB-causing mycobacteria: M. bovis, M. africanum, M. microti, M. canetti,  
M. caprae, M. pinnipedii, and M. mungi. These mycobacteria are sometimes called 
tuberculous mycobacteria since they can cause TB disease or other diseases very 
similar to TB. Mycobacterium tuberculosis is the most common cause of TB in 
humans; it is sometimes called the tubercle bacillus. 
negative pressure— the difference in air-pressure between two areas. A room that 
is under negative pressure has a lower pressure than adjacent areas, which keeps air 
from flowing out of the room and into adjacent rooms or areas. Negative pressure is 
also used to describe a nonpowered respirator.
negative pressure isolation room— see airborne infection isolation (AII) room
nontuberculous mycobacteria— mycobacteria that do not cause TB disease and 
are not usually spread from person to person; one example is M. avium-complex 
nucleic acid amplification (NAA)— a technique that amplifies (copies) DNA and 
RNA segments. Often used in assays to directly detect microorganisms in sputum 
specimens.
panel physicians— overseas health care providers who screen U.S. immigration 
applicants for TB disease
pathogenesis— how an infection or disease develops in the body
peripheral neuropathy— damage to the sensory nerves of the hands and feet, 
causing tingling, numbness, or pain in the hands and feet
personal respirators— special device designed to protect users from inhaling 
droplet nuclei; used in health care facilities and other settings where TB may be 
spread
polymerase chain reaction (PCR)— a type of NAA used to make many copies of a 
segment of DNA
poly-resistant TB— TB that is resistant to at least two TB treatment drugs (but not 
both isoniazid and rifampin, i.e., it is not the same as MDR TB)
PPD (purified protein derivative)— antigens such as the type of tuberculin used in 
the TST (see antigen)
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primary drug-resistance— drug-resistance caused by person-to-person transmission 
of drug-resistant organisms
pulmonary TB— TB disease that occurs in the lungs typically causing a cough and 
an abnormal chest x-ray; pulmonary TB is usually infectious if untreated. Most TB 
cases reported in the United States are pulmonary cases.
pyrazinamide (PZA)— first-line drug for the treatment of TB disease, may cause 
hepatitis and other adverse reactions in some patients
pyridoxine— another name for vitamin B6; it is given to prevent peripheral 
neuropathy; should always be given to pregnant and breastfeeding women on 
isoniazid; and to patients with diabetes or HIV
QuantiFERON®-TB Gold In-Tube test (QFT-GIT)— a blood test used to determine 
TB infection. The QFT-GIT measures the response to simulated TB proteins when 
they are mixed with a small amount of whole blood.
resistant— an organism’s ability to grow despite the presence of a particular drug
respiratory-protection controls— the third level in the hierarchy of TB infection-
control measures; used to minimize the risk for exposure to M. tuberculosis
rifabutin— a drug used to treat TB disease; used as a substitute for rifampin (RIF) in 
the treatment of all forms of TB
rifampin (RIF)— a key drug used to treat TB disease; also used for LTBI treatment. 
Rifampin has several possible side effects (for example, hepatitis, turning body fluids 
orange, drug-drug interactions, and flu-like symptoms).
rifapentine (RPT)— a drug used to treat TB disease; used once weekly with 
isoniazid during the continuation phase with selected HIV negative patients. Also 
used in the 12-dose regimen to treat LTBI.
secondary drug-resistance— also referred to as acquired drug-resistance; develops 
during TB treatment, either because the patient was not treated with the appropriate 
treatment regimen or because the patient did not follow the treatment regimen as 
prescribed
silicosis— a lung disease caused by inhaling silica dust, which is released by 
breaking rocks or is used in the production of glass and ceramics; occurs most often 
in mining, construction, and foundry workers
skin test conversion— a change in a skin test reaction from negative to positive 
between testing intervals 
smear— a specimen that has been smeared onto a glass slide, stained, washed in an 
acid solution, and then placed under the microscope for examination; used to detect 
acid-fast bacilli in a specimen
sputum— phlegm from deep in the lungs, collected in a sterile container for 
processing and examination
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surgical mask— device worn over the nose and mouth of a person with suspected 
or confirmed infectious TB disease to prevent infectious droplet nuclei from being 
spread (exhaled) into the air
susceptible— an organism’s ability to be killed by a particular drug
symptoms of TB disease— noticeable conditions caused by TB disease. The 
symptoms of pulmonary TB disease include coughing, pain in the chest when 
breathing or coughing, and coughing up sputum or blood. The general symptoms 
of TB disease (pulmonary or extrapulmonary) include weight loss, fatigue, malaise, 
fever, and night sweats. The symptoms of extrapulmonary TB disease depend on  
the part of the body that is affected by the disease.
targeted testing— a TB control strategy to identify persons at high risk for latent  
TB infection and persons at high risk for developing TB disease who would benefit 
from treatment
TB7.7— one of the antigens used in the QFT-GIT
TB risk assessment— an initial and ongoing evaluation of the risk for transmission 
of M. tuberculosis in a particular health care setting
TB testing— an administrative control measure in which evaluation for LTBI and  
TB disease are performed through initial and serial testing of health care workers
TB testing program— a program in which employees and residents of a facility 
are periodically tested for TB; done to identify people who have TB infection and 
possibly TB disease and to determine whether TB is being transmitted in the facility
T-SPOT®.TB Test (T-Spot)— a blood test used to determine TB infection; the  
T-Spot measures the number of T cells that have been activated by simulated  
M. tuberculosis antigens
transmission— the spread of an organism, such as M. tuberculosis, from one person 
to another. The probability of transmission depends on the contagiousness of the 
patient, the type of environment, the length of exposure, and the susceptibility of the 
exposed individual.
tubercle bacilli— another name for the Mycobacterium tuberculosis organisms that 
cause TB disease
tuberculin— a substance made from tubercle bacilli that have been killed by 
heating; used to determine whether a person has TB infection. Tuberculin is not  
a vaccine.
tuberculin skin test (TST)— a test used to detect TB infection (see Mantoux 
tuberculin skin test)
tuberculin unit— a standard strength of tuberculin used in the United States and 
Canada; a strength of 5 tuberculin units is used for the Mantoux TST 
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tumor necrosis factor-alpha (TNF-alpha) antagonists, inhibitors, or 
blockers— medications used to treat inflammatory or autoimmune diseases such 
as rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, and juvenile rheumatoid 
arthritis
two-step testing— a strategy used in TB testing programs to distinguish a boosted 
reaction (caused by TB infection that occurred many years ago) from a reaction 
caused by recent infection. If a person has a negative reaction to an initial skin test,  
a second test is given 1 to 3 weeks later; a positive reaction to the second test 
probably represents a boosted reaction, not recent infection. Two-step testing is used 
in many TB testing programs for skin testing employees when they start their job.
ultraviolet germicidal irradiation— the use of special lamps that give off ultraviolet 
light, which kills the tubercle bacilli contained in droplet nuclei
user seal check— formerly called “fit check”; procedure performed to check for  
the proper seal of a respirator each time a respirator is put on
ventilation systems— air systems designed to maintain negative pressure and  
to exhaust the air properly; designed to minimize the spread of TB in a health  
care facility 
window period— the time between a person’s last exposure to infectious TB and 
when a TST or IGRA can reliably detect infection with M. tuberculosis 
Xpert MTB/RIF assay— a nucleic acid amplification (NAA) test that simultaneously 
identifies Mycobacterium tuberculosis complex and rifampin resistance in a sputum 
sample
X-ray— a test that produces images of the inside the body. X-ray beams pass through 
the body and are absorbed in different amounts depending on the density of the 
material they pass through. Dense materials, such as bone, show up as white on 
X-rays. Air in the lungs shows up as black. Fat and muscle appear as varying shades 
of gray.
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